Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Darwinian evolution and tiding clones in multiple myeloma.

Literature DB >> 22859708

Darwinian evolution and tiding clones in multiple myeloma.

Nizar J Bahlis¹.
1. University of Calgary.

Abstract

In this issue of Blood, Keats et al,(1) Egan et al,(2) and Walker et al(3) provide a genome-wide snapshot of the clonal landscape in multiple myeloma(MM)illustrating the complexity of the evolutionary process and the dynamics of clonal evolution over time.

Entities: Disease

Mesh：

Year: 2012 PMID： 22859708 DOI： 10.1182/blood-2012-06-430645

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

Keyword Cloud
Cited

24 in total

Review 1. Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.

Authors: Matthew Ho Zhi Guang; Amanda McCann; Giada Bianchi; Li Zhang; Paul Dowling; Despina Bazou; Peter O'Gorman; Kenneth C Anderson
Journal: Leuk Lymphoma Date: 2017-06-13

2. Serum free light chain quantitative assays: Dilemma of a biomarker.

Authors: Giovanni Cigliana; Francesca Gulli; Cecilia Napodano; Krizia Pocino; Elena De Santis; Luigi Colacicco; Iole Cordone; Laura Conti; Umberto Basile
Journal: J Clin Lab Anal Date: 2017-04-26 Impact factor: 2.352

Review 3. Allogeneic stem cell transplantation for multiple myeloma: is there a future?

Authors: B Dhakal; D H Vesole; P N Hari
Journal: Bone Marrow Transplant Date: 2016-01-04 Impact factor: 5.483

Review 4. Genomic complexity of multiple myeloma and its clinical implications.

Authors: Salomon Manier; Karma Z Salem; Jihye Park; Dan A Landau; Gad Getz; Irene M Ghobrial
Journal: Nat Rev Clin Oncol Date: 2016-08-17 Impact factor: 66.675

Review 5. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Authors: Amit Agarwal; Irene M Ghobrial
Journal: Clin Cancer Res Date: 2012-12-05 Impact factor: 12.531

6. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma.

Authors: Andrew Spencer; Sung-Soo Yoon; Simon J Harrison; Shannon R Morris; Deborah A Smith; Richard A Brigandi; Jennifer Gauvin; Rakesh Kumar; Joanna B Opalinska; Christine Chen
Journal: Blood Date: 2014-07-29 Impact factor: 22.113

Darwinian evolution and tiding clones in multiple myeloma.

Review 1. Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.

2. Serum free light chain quantitative assays: Dilemma of a biomarker.

Review 3. Allogeneic stem cell transplantation for multiple myeloma: is there a future?

Review 4. Genomic complexity of multiple myeloma and its clinical implications.

Review 5. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

6. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma.

7. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.

Review 8. Molecular pathogenesis of multiple myeloma.

Review 9. Role of Circulating Tumor DNA in Hematological Malignancy.

10. Frequent occurrence of highly expanded but unrelated B-cell clones in patients with multiple myeloma.